GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » Beneish M-Score

Elutia (Elutia) Beneish M-Score : -3.23 (As of Apr. 27, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Elutia Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.23 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Elutia's Beneish M-Score or its related term are showing as below:

ELUT' s Beneish M-Score Range Over the Past 10 Years
Min: -3.39   Med: -3.23   Max: -1.2
Current: -3.23

During the past 6 years, the highest Beneish M-Score of Elutia was -1.20. The lowest was -3.39. And the median was -3.23.


Elutia Beneish M-Score Historical Data

The historical data trend for Elutia's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia Beneish M-Score Chart

Elutia Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -3.39 -1.20 -3.23

Elutia Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.20 -1.46 -2.26 -4.04 -3.23

Competitive Comparison of Elutia's Beneish M-Score

For the Medical Devices subindustry, Elutia's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Elutia's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Elutia's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Elutia's Beneish M-Score falls into.



Elutia Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Elutia for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.3505+0.528 * 1.1954+0.404 * 1.0525+0.892 * 0.9666+0.115 * 0.9853
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8473+4.679 * -0.023188-0.327 * 1.5026
=-3.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $5.96 Mil.
Revenue was 5.875 + 6.127 + 10.296 + 13.05 = $35.35 Mil.
Gross Profit was 2.126 + 2.841 + 0.98 + 6.331 = $12.28 Mil.
Total Current Assets was $31.25 Mil.
Total Assets was $43.43 Mil.
Property, Plant and Equipment(Net PPE) was $0.50 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.75 Mil.
Selling, General, & Admin. Expense(SGA) was $28.76 Mil.
Total Current Liabilities was $43.04 Mil.
Long-Term Debt & Capital Lease Obligation was $20.36 Mil.
Net Income was -9.314 + -9.747 + -10.621 + -7.974 = $-37.66 Mil.
Non Operating Income was -7.922 + -3.784 + -1.271 + -1.911 = $-14.89 Mil.
Cash Flow from Operations was -9.083 + -5.123 + -2.389 + -5.166 = $-21.76 Mil.
Total Receivables was $17.59 Mil.
Revenue was 6.587 + 5.849 + 12.638 + 11.495 = $36.57 Mil.
Gross Profit was 3.066 + 2.939 + 4.898 + 4.281 = $15.18 Mil.
Total Current Assets was $50.70 Mil.
Total Assets was $68.84 Mil.
Property, Plant and Equipment(Net PPE) was $0.57 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.73 Mil.
Selling, General, & Admin. Expense(SGA) was $35.11 Mil.
Total Current Liabilities was $42.62 Mil.
Long-Term Debt & Capital Lease Obligation was $24.26 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(5.959 / 35.348) / (17.587 / 36.569)
=0.168581 / 0.480926
=0.3505

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(15.184 / 36.569) / (12.278 / 35.348)
=0.415215 / 0.347346
=1.1954

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (31.253 + 0.504) / 43.428) / (1 - (50.699 + 0.565) / 68.841)
=0.268744 / 0.255327
=1.0525

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=35.348 / 36.569
=0.9666

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.733 / (3.733 + 0.565)) / (3.748 / (3.748 + 0.504))
=0.868544 / 0.881468
=0.9853

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(28.757 / 35.348) / (35.11 / 36.569)
=0.81354 / 0.960103
=0.8473

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((20.356 + 43.037) / 43.428) / ((24.26 + 42.615) / 68.841)
=1.459726 / 0.971441
=1.5026

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-37.656 - -14.888 - -21.761) / 43.428
=-0.023188

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Elutia has a M-score of -3.23 suggests that the company is unlikely to be a manipulator.


Elutia (Elutia) Business Description

Traded in Other Exchanges
N/A
Address
12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
Executives
Elutia Pipe Investment, Lp 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc 10 percent owner 688 PINE STREET, BURLINGTON VT 05401
Thomas Englese officer: Chief Commercial Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman director 452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes director 20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson officer: Chief Financial Officer C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p. 10 percent owner 36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams officer: Chief Scientific Officer C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck 10 percent owner C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp 10 percent owner 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards officer: GENERAL COUNSEL C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015